
For decades, the journey to bring a new medicine to market has been a high-stakes gamble, a process so fraught with failure that nine out of every ten promising compounds never reach patients after a decade or more of costly development. This long-standing paradigm is now facing a profound disruption from artificial intelligence, a force poised to unlock unprecedented efficiency










